Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 16, 2026 · most recent call
ABT’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Abbott Laboratories’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ABT daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
Reporting soon: earnings call Wednesday, Oct 21
A pre-earnings brief is ready for ABT: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $10.97B | +7.2% | $5.27 | +479.1% | 51.0% | 18.1% | 84.1% | $2.15B |
| FY2025 Q1 | $10.36B | +4.0% | $0.76 | +8.3% | 52.6% | 16.3% | 12.8% | $933M |
| FY2025 Q2 | $11.14B | +7.4% | $1.01 | +36.5% | 56.4% | 18.4% | 16.0% | $1.54B |
| FY2025 Q3 | $11.37B | +6.9% | $0.94 | 0.0% | 55.7% | 18.1% | 14.5% | $2.29B |
| FY2025 Q4 | $11.46B | +4.4% | $1.02 | -80.6% | 57.0% | 19.6% | 15.5% | $2.63B |
| FY2026 Q1 | $11.16B | +7.8% | $0.62 | -18.2% | 56.3% | 16.5% | 9.6% | $916M |
| FY2026 Q2Selected | $12.59B | +13.0% | $0.53 | -47.5% | 58.0% | 14.2% | 7.4% | $2.89B |
Management-stated figures from ABT’s newest call are part of Tellvest Pro.
On August 20, 2026, Abbott entered agreements to resolve the Gill lawsuit (a July 2024 Missouri jury awarded $495M, affirmed on appeal in May 2026, ~$600M with interest) plus NEC claims for approximately 2,000 additional infants for an aggregate of about $670 million. Abbott framed the agreements as a compromise of disputed claims, not an admission of liability, and a constructive step toward substantially resolving the necrotizing enterocolitis litigation.
What each event means for ABT’s sentiment score is part of Tellvest Pro.